Grit enters the in vivo Car-T race
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
Lilly joins the folate receptor arena
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
